ASH 2017 | Ibrutinib and FCR chemoimmunotherapy: improving complete remission in CLL patients?
Recent data have suggested that chronic lymphocytic leukemia (CLL) patients, in particular those with mutated immunoglobulin heavy chain genes, can have prolonged responses to FCR chemoimmunotherapy. In this interview, Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, dicusses the ecouraging results of a Phase II clinical trial (NCT02251548) investigating whether adding ibrutinib to the classic fludarabine, cyclophosphamide and rituximab (FCR) regimen would significantly improve the complete remission and minimal residual disease (MRD) negativity status of patients with CLL. Dr Brown also details the expansion of this trial folllowing its promising results. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
